TRAVERE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.26 USD | -2.41% |
|
-8.04% | -41.49% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 610 | 1,391 | 1,900 | 1,350 | 675.6 | 400.3 | - | - |
| Enterprise Value (EV) 1 | 416.3 | 1,245 | 1,900 | 1,275 | 486 | 518.4 | 469.7 | 400.3 |
| P/E ratio | -4.1 x | -7.66 x | -10.3 x | -4.81 x | -5.99 x | -1.75 x | -2.8 x | -10.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.48 x | 7.02 x | 8.35 x | 6.37 x | 4.65 x | 1.86 x | 1.33 x | 0.91 x |
| EV / Revenue | 2.37 x | 6.28 x | 8.35 x | 6.01 x | 3.35 x | 2.4 x | 1.55 x | 0.91 x |
| EV / EBITDA | -3.56 x | -8.21 x | -14.1 x | -5.46 x | -1.39 x | -2.47 x | -3.47 x | -5.67 x |
| EV / FCF | -7.13 x | -25.1 x | - | -6.84 x | -1.73 x | -2.69 x | -4.67 x | -17 x |
| FCF Yield | -14% | -3.98% | - | -14.6% | -57.8% | -37.1% | -21.4% | -5.87% |
| Price to Book | - | - | - | - | 3.33 x | 53.8 x | -3.91 x | - |
| Nbr of stocks (in thousands) | 42,958 | 51,052 | 61,226 | 64,174 | 75,146 | 76,109 | - | - |
| Reference price 2 | 14.20 | 27.26 | 31.04 | 21.03 | 8.990 | 5.260 | 5.260 | 5.260 |
| Announcement Date | 2/24/20 | 3/1/21 | 2/24/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 175.3 | 198.3 | 227.5 | 212 | 145.2 | 215.7 | 302.1 | 438.1 |
| EBITDA 1 | -117 | -151.6 | -135.1 | -233.5 | -349.6 | -209.9 | -135.3 | -70.55 |
| EBIT 1 | -137.4 | -176.2 | -161.8 | -266.6 | -388.1 | -261.3 | -200.2 | -95.34 |
| Operating Margin | -78.34% | -88.83% | -71.11% | -125.73% | -267.24% | -121.12% | -66.26% | -21.76% |
| Earnings before Tax (EBT) 1 | -146.4 | -188.8 | -179.7 | -278.2 | -376.1 | -241.6 | -189.7 | -98.54 |
| Net income 1 | -146.4 | -169.4 | -180.1 | -278.5 | -111.4 | -238 | -164.3 | -48.34 |
| Net margin | -83.51% | -85.43% | -79.16% | -131.35% | -76.7% | -110.33% | -54.39% | -11.04% |
| EPS 2 | -3.460 | -3.560 | -3.010 | -4.370 | -1.500 | -3.000 | -1.877 | -0.5125 |
| Free Cash Flow 1 | -58.41 | -49.51 | - | -186.5 | -280.7 | -192.5 | -100.7 | -23.5 |
| FCF margin | -33.31% | -24.96% | - | -87.96% | -193.26% | -89.24% | -33.32% | -5.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 3/1/21 | 2/24/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 68.22 | 57.25 | 48.49 | 54.17 | 53.5 | 55.87 | 56.99 | 59.7 | 37.1 | 45.06 | 45.15 | 50.48 | 55.81 | 71.77 | 50.01 |
| EBITDA 1 | -24.77 | -40.13 | -59.04 | -57.34 | -59.56 | -57.55 | -77.5 | - | -86.99 | -84.74 | -66.21 | -52.07 | -46.77 | -44.87 | - |
| EBIT 1 | -31.71 | -47.19 | -66.13 | -65.45 | -68.13 | -66.85 | -87.05 | -87.58 | -92.58 | -94.23 | -79.34 | -69.58 | -59.55 | -52.16 | - |
| Operating Margin | -46.49% | -82.43% | -136.39% | -120.83% | -127.36% | -119.66% | -152.73% | -146.71% | -249.59% | -209.13% | -175.71% | -137.85% | -106.71% | -72.68% | - |
| Earnings before Tax (EBT) 1 | -35.6 | -51.57 | -75.92 | -66.98 | -69.51 | -65.76 | -86.25 | -85.56 | -89.23 | -88.53 | -78.58 | -68.88 | -58.9 | -51.02 | - |
| Net income 1 | -35.64 | -51.57 | -75.97 | -67.03 | -69.66 | -65.82 | -86.33 | -85.63 | 150.7 | -90.17 | -76.52 | -65.43 | -56.66 | -39.51 | -48.51 |
| Net margin | -52.24% | -90.09% | -156.68% | -123.75% | -130.21% | -117.82% | -151.48% | -143.44% | 406.35% | -200.12% | -169.45% | -129.61% | -101.54% | -55.06% | -97% |
| EPS 2 | -0.5900 | -0.8400 | -1.200 | -1.050 | -1.090 | -1.030 | -1.270 | -1.130 | 1.970 | -1.180 | -0.9673 | -0.8236 | -0.7184 | -0.5045 | -0.5300 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/28/21 | 2/24/22 | 5/5/22 | 8/4/22 | 10/27/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/7/23 | 2/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 118 | 69.3 | - |
| Net Cash position 1 | 194 | 146 | - | 74.7 | 190 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.5624 x | -0.5124 x | - |
| Free Cash Flow 1 | -58.4 | -49.5 | - | -186 | -281 | -193 | -101 | -23.5 |
| ROE (net income / shareholders' equity) | -0.54% | -63.4% | -70.2% | -111% | -16.9% | -118% | -250% | -617% |
| ROA (Net income/ Total Assets) | - | - | - | - | -15.2% | -31.3% | -51.7% | - |
| Assets 1 | - | - | - | - | 731 | 759.9 | 317.6 | - |
| Book Value Per Share 2 | - | - | - | - | 2.700 | 0.1000 | -1.350 | - |
| Cash Flow per Share 2 | - | -0.9000 | -0.2500 | -2.920 | -3.770 | -0.9100 | -0.8100 | - |
| Capex 1 | 0.2 | 6.77 | 5.1 | 0.19 | 0.67 | 2.1 | 3.98 | 8.5 |
| Capex / Sales | 0.11% | 3.41% | 2.24% | 0.09% | 0.46% | 0.97% | 1.32% | 1.94% |
| Announcement Date | 2/24/20 | 3/1/21 | 2/24/22 | 2/23/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
5.26
USD
Average target price
14.79
USD
Spread / Average Target
+181.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.49% | 400M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TVTX Stock
- Financials Travere Therapeutics, Inc.
